{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T03:53:18Z","timestamp":1780717998794,"version":"3.54.1"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T00:00:00Z","timestamp":1539302400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/igo\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.vaccine.2018.08.039","type":"journal-article","created":{"date-parts":[[2018,8,25]],"date-time":"2018-08-25T01:27:04Z","timestamp":1535160424000},"page":"A140-A145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"S1","title":["New human rabies vaccines in the pipeline"],"prefix":"10.1016","volume":"37","author":[{"given":"Anthony R.","family":"Fooks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley C.","family":"Banyard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildegund C.J.","family":"Ertl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.08.039_b0005","article-title":"Estimating the global burden of endemic canine rabies","volume":"9","author":"Hampson","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2018.08.039_b0010","doi-asserted-by":"crossref","DOI":"10.1007\/s00705-018-3814-x","article-title":"Taxonomy of the order mononegavirales: update 2018","author":"Amarasinghe","year":"2018","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2018.08.039_b0015","first-page":"185","article-title":"Ability of rabies vaccine strains to elicit cross-neutralising antibodies","volume":"125","author":"Brookes","year":"2006","journal-title":"Dev Biol (Basel)"},{"key":"10.1016\/j.vaccine.2018.08.039_b0020","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1128\/JVI.75.7.3268-3276.2001","article-title":"Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity","volume":"75","author":"Badrane","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.08.039_b0025","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1086\/313632","article-title":"Rabies","volume":"30","author":"Plotkin","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.08.039_b0030","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/0035-9203(76)90037-7","article-title":"The clinical picture of rabies in man","volume":"70","author":"Warrell","year":"1976","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2018.08.039_b0035","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/ana.24016","article-title":"Phylogenetic and epidemiologic evidence of multiyear incubation in human rabies","volume":"75","author":"Boland","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.vaccine.2018.08.039_b0040","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4103\/0972-2327.99728","article-title":"Rabies viral encephalitis with proable 25 year incubation period!","volume":"15","author":"Shankar","year":"2012","journal-title":"Ann Indian Acad Neurol"},{"key":"10.1016\/j.vaccine.2018.08.039_b0045","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1056\/NEJMoa050382","article-title":"Survival after treatment of rabies with induction of coma","volume":"352","author":"Willoughby","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.08.039_b0050","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1017\/cjn.2015.331","article-title":"Critical appraisal of the Milwaukee protocol for rabies: this failed approach should be abandoned","volume":"43","author":"Zeiler","year":"2016","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.vaccine.2018.08.039_b0055","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/bmj.299.6703.830","article-title":"Failure of interferon alfa and tribavirin in rabies encephalitis","volume":"299","author":"Warrell","year":"1989","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2018.08.039_b0060","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ana.410160116","article-title":"Human leukocyte interferon administration to patients with symptomatic and suspected rabies","volume":"16","author":"Merigan","year":"1984","journal-title":"Ann Neurol"},{"key":"10.1016\/j.vaccine.2018.08.039_b0065","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1201-9712(03)90046-4","article-title":"Paralytic complications following intravenous rabies immune globulin treatment in a patient with furious rabies","volume":"7","author":"Hemachudha","year":"2003","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.08.039_b0070","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1708-8305.1999.tb00525.x","article-title":"Economic issues in postexposure rabies treatment","volume":"6","author":"Wilde","year":"1999","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2018.08.039_b0075","unstructured":"World Health Organization. WHO Expert Consultation on Rabies. Third report. World Health Organization Technical Report Series; 2018. p. 1\u2013195."},{"key":"10.1016\/j.vaccine.2018.08.039_b0080","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1006\/clin.1994.1088","article-title":"Long-term humoral and cellular immunity after vaccination with cell culture rabies vaccines in man","volume":"71","author":"Thraenhart","year":"1994","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.vaccine.2018.08.039_b0085","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1016\/j.vaccine.2008.04.081","article-title":"Intradermal pre-exposure rabies vaccine elicits long lasting immunity","volume":"26","author":"Brown","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.039_b0090","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1016\/j.vaccine.2010.03.039","article-title":"The immune response to rabies virus infection and vaccination","volume":"28","author":"Johnson","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.039_b0095","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.4049\/jimmunol.1000844","article-title":"NK cells as effectors of acquired immune responses: effector CD4+ T cell-dependent activation of NK cells following vaccination","volume":"185","author":"Horowitz","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.08.039_b0100","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1006\/viro.1995.0049","article-title":"Immune effector mechanisms required for protection to rabies virus","volume":"214","author":"Xiang","year":"1995","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.08.039_b0105","unstructured":"WHO Expert Consultation on rabies. World Health Organ Tech Rep Ser. 2005; 931: 1\u201388."},{"key":"10.1016\/j.vaccine.2018.08.039_b0110","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1016\/j.vaccine.2009.06.095","article-title":"Antibodies induced by vaccination with purified chick embryo cell culture vaccine (PCECV) cross-neutralize non-classical bat lyssavirus strains","volume":"27","author":"Malerczyk","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.039_b0115","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.bbrc.2005.08.209","article-title":"Viruses selectively upregulate Toll-like receptors in the central nervous system","volume":"336","author":"McKimmie","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.vaccine.2018.08.039_b0120","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1080\/13550280802008297","article-title":"Up-regulation of chemokine gene transcripts and T-cell infiltration into the central nervous system and dorsal root ganglia are characteristics of experimental European bat lyssavirus type 2 infection of mice","volume":"14","author":"Mansfield","year":"2008","journal-title":"J Neurovirol"},{"key":"10.1016\/j.vaccine.2018.08.039_b0125","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/imm.12793","article-title":"Here, there and everywhere: T follicular helper cells on the move","volume":"152","author":"Ma","year":"2017","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2018.08.039_b0130","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/003655401750174183","article-title":"Failure of pre- and postexposure rabies vaccinations in a child infected with HIV","volume":"33","author":"Pancharoen","year":"2001","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.08.039_b0135","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1056\/NEJMoa051568","article-title":"An antibody-deficiency syndrome due to mutations in the CD19 gene","volume":"354","author":"van Zelm","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.08.039_b0140","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2249.2012.04592.x","article-title":"Developments in rabies vaccines","volume":"169","author":"Hicks","year":"2012","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2018.08.039_b0145","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1586\/erv.11.140","article-title":"From brain passage to cell adaptation: the road of human rabies vaccine development","volume":"10","author":"Wu","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.08.039_b0150","doi-asserted-by":"crossref","first-page":"7605","DOI":"10.1016\/j.vaccine.2007.08.054","article-title":"Failures of post-exposure rabies prophylaxis","volume":"25","author":"Wilde","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.039_b0155","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2471\/BLT.16.173039","article-title":"Pre-exposure rabies prophylaxis: a systematic review","volume":"95","author":"Kessels","year":"2017","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2018.08.039_b0160","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.vaccine.2005.03.059","article-title":"Cost comparison of rabies pre-exposure vaccination with post-exposure treatment in Thai children","volume":"24","author":"Chulasugandha","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.039_b0165","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.vaccine.2014.02.065","article-title":"Development of a multivalent paediatric human vaccine for rabies virus in combination with Measles-Mumps-Rubella (MMR)","volume":"32","author":"Fooks","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.039_b0170","doi-asserted-by":"crossref","first-page":"9217","DOI":"10.1128\/JVI.00995-13","article-title":"Reinvestigating the role of IgM in rabies virus postexposure vaccination","volume":"87","author":"Dorfmeier","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.08.039_b0175","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.virol.2013.12.029","article-title":"Protection of non-human primates against rabies with an adenovirus recombinant vaccine","volume":"450\u2013451","author":"Xiang","year":"2014","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.08.039_b0180","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0769-2617(85)80127-1","article-title":"Localization of immunogenic domains on the rabies virus glycoprotein","volume":"136","author":"Wunner","year":"1985","journal-title":"Annales de l\u2019Institut Pasteur\/Virologie"},{"key":"10.1016\/j.vaccine.2018.08.039_b0185","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1016\/j.vaccine.2014.02.031","article-title":"Rabies virus-like particles expressed in HEK293 cells","volume":"32","author":"Fontana","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.039_b0190","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s10529-015-1787-3","article-title":"Transient expression of rabies virus G-glycoprotein using BHK-21 cells cultured in suspension","volume":"37","author":"Fern\u00e1ndez-N\u00fa\u00f1ez","year":"2015","journal-title":"Biotechnol Lett"},{"key":"10.1016\/j.vaccine.2018.08.039_b0195","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1006\/prep.1996.0026","article-title":"Purification of a secreted form of recombinant rabies virus glycoprotein: comparison of two affinity tags","volume":"7","author":"Wojczyk","year":"1996","journal-title":"Protein Expr Purif"},{"key":"10.1016\/j.vaccine.2018.08.039_b0200","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1385\/MB:28:3:241","article-title":"Appropriate glycosylation of recombinant proteins for human use: implications of choice of expression system","volume":"28","author":"Brooks","year":"2004","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.vaccine.2018.08.039_b0205","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/0042-6822(89)90551-5","article-title":"Immunogenic and protective properties of rabies virus glycoprotein expressed by baculovirus vectors","volume":"173","author":"Prehaud","year":"1989","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.08.039_b0210","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10616-008-9139-y","article-title":"Growth of recombinant Drosophila melanogaster Schneider 2 cells producing rabies virus glycoprotein in bioreactor employing serum-free medium","volume":"57","author":"Galesi","year":"2008","journal-title":"Cytotechnology"},{"key":"10.1016\/j.vaccine.2018.08.039_b0215","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0264-410X(98)00196-0","article-title":"Studies on the structures and antigenic properties of rabies virus glycoprotein analogues produced in yeast cells","volume":"17","author":"Sakamoto","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.039_b0220","first-page":"1484","article-title":"Expression of the rabies virus glycoprotein in transgenic tomatoes","volume":"13","author":"McGarvey","year":"1995","journal-title":"Biotechnology (NY)"},{"key":"10.1016\/j.vaccine.2018.08.039_b0225","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s11248-009-9278-8","article-title":"Expression of rabies virus G protein in carrots (Daucus carota)","volume":"18","author":"Rojas-Anaya","year":"2009","journal-title":"Transgenic Res"},{"key":"10.1016\/j.vaccine.2018.08.039_b0230","first-page":"477","article-title":"Development of an edible rabies vaccine in maize using the Vnukovo strain","volume":"131","author":"Loza-Rubio","year":"2008","journal-title":"Dev Biol (Basel)"},{"key":"10.1016\/j.vaccine.2018.08.039_b0235","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1016\/S0264-410X(02)00260-8","article-title":"Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine","volume":"20","author":"Yusibov","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.039_b0240","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.vaccine.2016.03.070","article-title":"A rabies vaccine adjuvanted with saponins from leaves of the soap tree (Quillaja brasiliensis) induces specific immune responses and protects against lethal challenge","volume":"34","author":"Yendo","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.039_b0245","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.vaccine.2008.01.043","article-title":"A CpG oligodeoxynucleotide acts as a potent adjuvant for inactivated rabies virus vaccine","volume":"26","author":"Wang","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.039_b0250","doi-asserted-by":"crossref","first-page":"7127","DOI":"10.1016\/j.vaccine.2017.10.097","article-title":"A phase II randomized study to determine the safety and immunogenicity of the novel PIKA rabies vaccine containing the PIKA adjuvant using an accelerated regimen","volume":"35","author":"Kalimuddin","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.039_b0255","doi-asserted-by":"crossref","DOI":"10.1089\/vim.2017.0093","article-title":"Enhanced immune response to rabies viruses by the use of a liposome adjuvant in vaccines","author":"Miao","year":"2017","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2018.08.039_b0260","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/laban.988","article-title":"A novel adjuvant promises improved rabies vaccine","volume":"45","author":"Nicholson","year":"2016","journal-title":"Lab Anim (NY)"},{"key":"10.1016\/j.vaccine.2018.08.039_b0265","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00705-015-2704-8","article-title":"Immunoenhancement with flagellin as an adjuvant to whole-killed rabies vaccine in mice","volume":"161","author":"Xiao","year":"2016","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2018.08.039_b0270","doi-asserted-by":"crossref","first-page":"7310","DOI":"10.1073\/pnas.93.14.7310","article-title":"Highly stable expression of a foreign gene from rabies virus vectors","volume":"93","author":"Mebatsion","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2018.08.039_b0275","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1348-0421.2005.tb03692.x","article-title":"Characterization of M gene-deficient rabies virus with advantages of effective immunization and safety as a vaccine strain","volume":"49","author":"Ito","year":"2005","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2018.08.039_b0280","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.virusres.2005.03.011","article-title":"Characterization of P gene-deficient rabies virus: propagation, pathogenicity and antigenicity","volume":"111","author":"Morimoto","year":"2005","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2018.08.039_b0285","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1086\/605949","article-title":"Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates","volume":"200","author":"Cenna","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.08.039_b0290","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1348-0421.2006.tb03785.x","article-title":"Characterization of recombinant rabies virus carrying double glycoprotein genes","volume":"50","author":"Hosokawa-Muto","year":"2006","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2018.08.039_b0295","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0264-410X(98)00279-5","article-title":"The effect of pre-existing adenovirus-specific immunity on immune responses induced by recombinant adenovirus expressing glycoprotein D of bovine herpesvirus type 1","volume":"17","author":"Papp","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.039_b0300","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0264-410X(95)93136-W","article-title":"Passively administered antibody suppresses the induction of measles virus antibodies by vaccinia-measles recombinant viruses","volume":"13","author":"Galletti","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.039_b0305","doi-asserted-by":"crossref","first-page":"5488","DOI":"10.1016\/j.vaccine.2016.09.062","article-title":"Delivery methods to increase cellular uptake and immunogenicity of DNA vaccines","volume":"34","author":"Jorritsma","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.039_b0310","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.08.039_b0315","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1006\/viro.1995.1289","article-title":"Immune responses to nucleic acid vaccines to rabies virus","volume":"209","author":"Xiang","year":"1995","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.08.039_b0320","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0264-410X(96)00281-2","article-title":"Nanogram quantities of plasmid DNA encoding the rabies virus glycoprotein protect mice against lethal rabies virus infection","volume":"15","author":"Ray","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.039_b0325","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0264-410X(97)00204-1","article-title":"DNA-based immunization for exploring the enlargement of immunological cross-reactivity against the lyssaviruses","volume":"16","author":"Bahloul","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.039_b0330","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0264-410X(01)00392-9","article-title":"One-time gene gun or intramuscular rabies DNA vaccination of non-human primates: comparison of neutralizing antibody responses and protection against rabies virus 1 year after vaccination","volume":"20","author":"Lodmell","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.039_b0335","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/S0264-410X(02)00143-3","article-title":"Rabies DNA vaccination of non-human primates: post-exposure studies using gene gun methodology that accelerates induction of neutralizing antibody and enhances neutralizing antibody titers","volume":"20","author":"Lodmell","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.039_b0340","first-page":"1072","article-title":"Pre-clinical toxicity & immunobiological evaluation of DNA rabies vaccine & combination rabies vaccine in rhesus monkeys (Macaca mulatta)","volume":"137","author":"Kumar","year":"2013","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.vaccine.2018.08.039_b0345","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1310566","article-title":"Efficacy trial of a DNA\/rAd5 HIV-1 preventive vaccine","volume":"369","author":"Hammer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.08.039_b0350","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.08.039_b0355","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/JVI.77.11.6305-6313.2003","article-title":"Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene","volume":"77","author":"Casimiro","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.08.039_b0360","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1182\/blood-2007-02-062117","article-title":"Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines","volume":"110","author":"Tatsis","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2018.08.039_b0365","doi-asserted-by":"crossref","first-page":"11603","DOI":"10.1128\/JVI.75.23.11603-11613.2001","article-title":"Replication-defective vector based on a chimpanzee adenovirus","volume":"75","author":"Farina","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.08.039_b0370","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3201\/eid1210.060078","article-title":"Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa","volume":"12","author":"Xiang","year":"2006","journal-title":"Emerging Infect Dis"},{"key":"10.1016\/j.vaccine.2018.08.039_b0375","first-page":"80","article-title":"Development of oral vaccines for human use","volume":"2","author":"Fooks","year":"2000","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.vaccine.2018.08.039_b0380","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000490","article-title":"Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass","volume":"2","author":"Alcock","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2018.08.039_b0385","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1089\/hum.2014.007","article-title":"Challenges in manufacturing adenoviral vectors for global vaccine product deployment","volume":"25","author":"Vellinga","year":"2014","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.vaccine.2018.08.039_b0390","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/vr.123.19.481","article-title":"First field trial of fox vaccination against rabies using a vaccinia-rabies recombinant virus","volume":"123","author":"Pastoret","year":"1988","journal-title":"Vet Rec"},{"key":"10.1016\/j.vaccine.2018.08.039_b0395","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/0264-410X(91)90152-V","article-title":"Efficacy studies on a canarypox-rabies recombinant virus","volume":"9","author":"Taylor","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.039_b0400","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/0140-6736(92)92027-D","article-title":"Immunisation with canarypox virus expressing rabies glycoprotein","volume":"339","author":"Cadoz","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.08.039_b0405","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1016\/j.vaccine.2007.02.084","article-title":"Generation and evaluation of a recombinant modified vaccinia virus Ankara vaccine for rabies","volume":"25","author":"Weyer","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.039_b0410","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/0264-410X(95)00226-Q","article-title":"Comparison of the efficacy of replication-defective adenovirus and Nyvac poxvirus as vaccine vectors in mice","volume":"14","author":"Gonin","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.039_b0415","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1056\/NEJMoa010560","article-title":"Human infection due to recombinant vaccinia-rabies glycoprotein virus","volume":"345","author":"Rupprecht","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.08.039_b0420","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1128\/JVI.02886-12","article-title":"A novel rabies vaccine based on a recombinant parainfluenza virus 5 expressing rabies virus glycoprotein","volume":"87","author":"Chen","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.08.039_b0425","doi-asserted-by":"crossref","first-page":"8241","DOI":"10.1128\/JVI.00519-11","article-title":"Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats","volume":"85","author":"Ge","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.08.039_b0430","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.vaccine.2007.12.050","article-title":"A recombinant pseudorabies virus expressing rabies virus glycoprotein: safety and immunogenicity in dogs","volume":"26","author":"Yuan","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.039_b0435","doi-asserted-by":"crossref","first-page":"17091","DOI":"10.1038\/nrdp.2017.91","article-title":"Rabies","volume":"3","author":"Fooks","year":"2017","journal-title":"Nat Rev Dis Primers"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1831168X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1831168X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:34:11Z","timestamp":1759401251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1831168X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":87,"alternative-id":["S0264410X1831168X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.08.039","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New human rabies vaccines in the pipeline","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.08.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}